400 related articles for article (PubMed ID: 28874187)
21. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
22. Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry.
Mercado M; Abreu C; Vergara-López A; González-Virla B; Espinosa-de-Los-Monteros AL; Sosa-Eroza E; Cadena-Obando D; Cuevas-Ramos D; Portocarrero-Ortiz LA; Pérez-Reyes SP; Mercado-Cherem A; Ibarra-Salce R; Talavera JO
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32944780
[TBL] [Abstract][Full Text] [Related]
23. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.
Abe T; Lüdecke DK
Eur J Endocrinol; 2001 Aug; 145(2):137-45. PubMed ID: 11454508
[TBL] [Abstract][Full Text] [Related]
24. Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes.
Nishioka H; Fukuhara N; Horiguchi K; Yamada S
J Neurosurg; 2014 Sep; 121(3):505-10. PubMed ID: 25014437
[TBL] [Abstract][Full Text] [Related]
25. Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: A long-term single-center experience.
Lv L; Hu Y; Zhou P; Zhang S; Yin S; Zhang N; Jiang S
Clin Neurol Neurosurg; 2018 Apr; 167():24-30. PubMed ID: 29433055
[TBL] [Abstract][Full Text] [Related]
26. Long-term primary medical therapy with somatostatin analogs in acromegaly.
Su DH; Liao KM; Chen HW; Chang TC
J Formos Med Assoc; 2006 Aug; 105(8):664-9. PubMed ID: 16935768
[TBL] [Abstract][Full Text] [Related]
27. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly.
Freda PU; Wardlaw SL; Post KD
J Neurosurg; 1998 Sep; 89(3):353-8. PubMed ID: 9724106
[TBL] [Abstract][Full Text] [Related]
28. Surgical-pharmacological interactions in the treatment of acromegaly.
Abreu C; Guinto G; Mercado M
Expert Rev Endocrinol Metab; 2019 Jan; 14(1):35-42. PubMed ID: 30595057
[TBL] [Abstract][Full Text] [Related]
29. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission.
Starke RM; Raper DM; Payne SC; Vance ML; Oldfield EH; Jane JA
J Clin Endocrinol Metab; 2013 Aug; 98(8):3190-8. PubMed ID: 23737543
[TBL] [Abstract][Full Text] [Related]
30. Pitfalls in early biochemical evaluation after transsphenoidal surgery in patients with acromegaly.
Nishioka H; Fukuhara N; Yamaguchi-Okada M; Takeshita A; Takeuchi Y; Yamada S
Endocr J; 2017 Nov; 64(11):1073-1078. PubMed ID: 28835593
[TBL] [Abstract][Full Text] [Related]
31. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial.
Mao ZG; Zhu YH; Tang HL; Wang DY; Zhou J; He DS; Lan H; Luo BN; Wang HJ
Eur J Endocrinol; 2010 Apr; 162(4):661-6. PubMed ID: 20061334
[TBL] [Abstract][Full Text] [Related]
32. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
33. Predictive model of surgical remission in acromegaly: age, presurgical GH levels and Knosp grade as the best predictors of surgical remission.
Araujo-Castro M; Pascual-Corrales E; Martínez-Vaello V; Baonza Saiz G; Quiñones de Silva J; Acitores Cancela A; García Cano AM; Rodríguez Berrocal V
J Endocrinol Invest; 2021 Jan; 44(1):183-193. PubMed ID: 32441006
[TBL] [Abstract][Full Text] [Related]
34. Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.
Helseth R; Carlsen SM; Bollerslev J; Svartberg J; Øksnes M; Skeie S; Fougner SL
Endocrine; 2016 Feb; 51(2):298-307. PubMed ID: 26179177
[TBL] [Abstract][Full Text] [Related]
35. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
36. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure.
Tindall GT; Oyesiku NM; Watts NB; Clark RV; Christy JH; Adams DA
J Neurosurg; 1993 Feb; 78(2):205-15. PubMed ID: 8421204
[TBL] [Abstract][Full Text] [Related]
37. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
Campbell PG; Kenning E; Andrews DW; Yadla S; Rosen M; Evans JJ
Neurosurg Focus; 2010 Oct; 29(4):E5. PubMed ID: 20887130
[TBL] [Abstract][Full Text] [Related]
38. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly.
Bourdelot A; Coste J; Hazebroucq V; Gaillard S; Cazabat L; Bertagna X; Bertherat J
Eur J Endocrinol; 2004 Jun; 150(6):763-71. PubMed ID: 15191345
[TBL] [Abstract][Full Text] [Related]
39. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
Hazer DB; Işık S; Berker D; Güler S; Gürlek A; Yücel T; Berker M
J Neurosurg; 2013 Dec; 119(6):1467-77. PubMed ID: 24074496
[TBL] [Abstract][Full Text] [Related]
40. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
Oshino S; Saitoh Y; Kasayama S; Arita N; Ohnishi T; Kohara H; Izumoto S; Yoshimine T
Endocr J; 2006 Feb; 53(1):125-32. PubMed ID: 16543682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]